Archives

by in
Entry Author Date Location
Sold For Parts, Accelerator Grad Allozyne Reaches End of the Line 09/18/14 Seattle
West Coast Biotech Roundup: Seragon, Ambrx, Pregenen, and More 07/03/14 San Diego
San Diego’s Ambrx Withdraws IPO, Citing Market Conditions 06/30/14 San Diego
West Coast Biotech Roundup: Alder IPO, Exelixis, Corcept, and More 05/09/14 San Diego
San Diego’s Ambrx Files for IPO to Advance Antibody-Drug Conjugates 05/05/14 San Diego
New Ambrx CEO Discusses Latest Deal, with China’s Zhejiang Medicine 06/18/13 San Diego
San Diego Life Sciences Roundup: Receptos, Arena, NuVasive, & More 05/09/13 San Diego
From Assets to Zen: Building Successful Drug Hunting Relationships 04/22/13 San Diego
San Diego Life Sciences Roundup: Receptos IPO, Isis, Versant, & More 04/12/13 San Diego
San Diego’s Ambrx Working with Astellas to Develop Anti-Cancer Drugs 04/08/13 San Diego
San Diego Life Sciences Roundup: Illumina, Santarus, Accelrys, & More 01/18/13 San Diego
SD Life Sciences Roundup: Ambrx Gets Big Partner, GenMark, & More 06/21/12 National
Merck Bets $15M on Ambrx’s “Smart Bomb” Antibodies 06/18/12 San Diego
SD Biotech Roundup: Elevation Pharmaceuticals, BioSurplus, and More 05/17/12 San Diego
Targeted Cancer Drugs With Punch: The Next Big Class of Antibodies 05/16/12 National
Merck Returns to SD, Pouring $90M Into New Schultz-Led Institute 03/15/12 San Diego
Allozyne Raises More VC Cash, Looks to FDA Meeting After Poniard Deal Fizzles 12/23/11 Seattle
Celgene To Pump $45M into Quanticel to Discover Cancer Drugs, Gets Option To Acquire 11/04/11 San Francisco
Ambrx Grabs $24M Upfront in New Diabetes, Heart Failure Research Deal With Bristol-Myers 09/22/11 San Diego
Zymeworks Snags $187M Deal With Merck to Discover Multi-Pronged Antibodies 08/29/11 Seattle
Anaphore Snags $110M Deal With Mitsubishi Tanabe to Make Drugs for Immune Disorders 12/13/10 San Diego
Sutro Biopharma Grabs $36.5M in Venture Deal to Make “Biobetters” 11/17/10 San Francisco
Novartis-backed Genomics Institute Names Martin Seidel as New Director, Replacing Peter Schultz 10/05/10 San Diego
How Novartis Got Its Vaccines Groove Back, Intellikine Gets a Drug Development Deal, Ambrx CEO Departs, & More San Diego Life Sciences News 07/15/10 San Diego
Allozyne, After a Stealthy Year on a Slim Budget, Re-Emerges with MS Drug and Fat Pipeline 07/14/10 Seattle
Peter Schultz Exits Top Job at Genomics Institute of the Novartis Research Foundation 07/14/10 San Diego
Ambrx CEO Steve Kaldor Departs 07/12/10 San Diego
The 20-Year Outlook for San Diego Life Sciences: Sold Out? Not Anymore 03/15/10 San Diego
The 20-Year Future of San Diego Biotech, Coming March 31 03/09/10 San Diego
What Will San Diego’s Biotech Hub Look Like in 20 Years? Xconomy Event Takes Long View 02/16/10 San Diego
Page 1 of 2 next page »